Heterozygous familial hypercholesterolemia was associated with increased type 2 diabetes risk, especially among those with obesity and statin use.

HC Wainwright restated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research report report published on Wednesday morning,Benzinga reports. The firm currently ...

The trial of the combination of obicetrapib and ezetimibe is designed to work for patients whom existing cholesterol ...

China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

During the Phase III BROOKLYN trial, patients were randomly assigned in a 2:1 ratio to receive either obicetrapib 10mg or a ...

Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...

Dutch biotech NewAmsterdam Pharma (NASDAQ:NAMS) announced Wednesday that its oral anti-cholesterol therapy containing ...

Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of ...

Learn about typical dosages of atorvastatin oral tablet for high cholesterol and heart-related risks, including what’s considered a low dose versus a high dose of this statin.

NewAmsterdam Pharma’s lead cardio program obicetrapib passed another Phase 3 trial, demonstrating its ability to lower “bad ...